The AJMC® Immuno-Oncology compendium is a comprehensive resource for clinical news and expert insights for treatments that utilize the body's immune system to fight cancer, such as immune checkpoint inhibitors and chimeric antigen receptor T-cell therapies.
May 17th 2024
The FDA has approved tarlatamab (Imdelltra; Amgen), a novel bispecific T-cell engager, to treat patients with extensive-stage small cell lung cancer (SCLC).
Opdivo, Yervoy Combination Approved for Certain Colorectal Cancers
July 12th 2018Yesterday, drug manufacturer Bristol-Myers Squibb announced that the FDA has approved the combination nivolumab (Opdivo) plus low-dose ipilimumab (Yervoy) for the treatment of adult and pediatric patients aged 12 years and older with microsatellite instability high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer (mCRC) that has progressed following a fluoropyrimidine, oxaliplatin, or irinotecan-based chemotherapy treatment.
Read More
BrainChild-01 Will Evaluate CAR T Cells in Pediatric CNS Tumors
July 5th 2018The trial is designed to test chimeric antigen receptor (CAR) T-cell therapy in children and young adults with relapsed/refractory brain and central nervous system (CNS) tumors, wherein the modified CAR T cells will be directly injected at the site of tumor resection or into the ventricular system of the CNS.
Read More
AbbVie and Calibr to Collaborate on CAR T-Cell Development
June 29th 2018Drug manufacturer AbbVie, and a nonprofit drug discovery division of Scripps Research, Calibr, announced earlier this week that they are partnering to develop chimeric antigen receptor (CAR-T) cell therapies primarily aimed at treating cancer, particularly, solid tumors.
Read More
Tecentriq–Chemotherapy Combination Demonstrates Increased Survival in ES-SCLC
June 28th 2018This week, drug maker Roche released positive data from its phase 3 IMpower133 study that investigated an immunotherapy-based combination of atezolizumab (Tecentriq) and chemotherapy in the treatment of extensive-stage small cell lung cancer (ES-SCLC).
Read More
Immunotherapy-Based Combination Improves Survival in SCLC for First Time in Phase 3 Study
June 25th 2018First-line treatment with atezolizumab plus chemotherapy helped patients with previously untreated extensive-stage small cell lung cancer (SCLC) live significantly longer than those treated with chemotherapy alone.
Read More
FDA Warns Efficacy Concerns in Some Patients Taking Keytruda, Tecentriq
June 21st 2018In a statement released yesterday, the FDA has announced that it is restricting the use of pembrolizumab (Keytruda) and atezolizumab (Tecentriq) for patients with locally advanced or metastatic urothelial cancer who are not eligible for cisplatin-containing therapy.
Read More
Nivolumab Gains First Indication in China for NSCLC
June 20th 2018Last week, Bristol-Myers Squibb announced that the China National Drug Administration approved the country’s first immuno-oncology and first PD-1 therapy, nivolumab (Opdivo), for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC).
Read More
RA Drug May Reduce Toxicity Caused By CAR T Treatment
June 15th 2018Last year, the FDA expanded the indications of rheumatoid arthritis (RA) drug tocilizumab (Actemra) to include the treatment of cytokine release syndrome (CRS) caused by CAR T-cell therapy. Recently, 2 studies have identified another rheumatoid arthritis drug that could be more effective in the treatment of CRS.
Read More
Pembrolizumab Indications Expand to Include Cervical Cancer
June 13th 2018Yesterday, the FDA announced that it has expanded the indications of pembrolizumab (Keytruda) to include recurrent or metastatic cervical cancer with disease progression on or after chemotherapy whose tumors express PD-L1.
Read More
This Week in Managed Care: June 1, 2018
June 1st 2018This week, the top managed care stories include Senator Bill Cassidy's new plan to lower healthcare costs; policy recommendations from the American Diabetes Association on how to lower insulin prices; and coverage from the American Society of Clinical Oncology annual meeting.
Watch
CAR T Therapy Case Study Shows Early Success in Treatment of Acute Myeloid Leukemia
May 9th 2018A new case study found that an acute myeloid leukemia patient has remained cancer free for 9 months following treatment with the chimeric antigen receptor (CAR) T-cell treatment, CYAD-01, and a bone marrow transplant.
Read More
FDA Approves CAR T-Cell Treatment Kymriah for Adult B-Cell Lymphoma
May 2nd 2018Tisagenlecleucel, sold as Kymriah, has gained its second indication following the FDA's approval of the chimeric antigen receptor T-cell therapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma, the most common form of non-Hodgkin lymphoma.
Read More
FDA Grants Priority Review for Pembrolizumab, Chemotherapy Combination in NSCLC
April 30th 2018The FDA has granted priority review to Merck’s supplemental Biologics License Application for pembrolizumab (Keytruda) in combination with pemetrexed (Alimta) and platinum chemotherapy as first-line treatment for patients with metastatic nonsquamous non–small cell lung cancer (NSCLC). The FDA is set to make a decision by September 23.
Read More